Medincell Under Pressure After Uzedy’s 2025 Sales Report, Olanzapine LAI Progress in Focus
- Why Is Medincell’s Stock Struggling Despite Uzedy’s Growth?
- Olanzapine LAI: What’s the FDA Timeline?
- How Does Medincell’s Pipeline Stack Up Financially?
- FAQ: Medincell’s 2025-2026 Outlook
Medincell’s stock faces renewed pressure following Teva Pharmaceuticals’ 2025 annual results, which revealed Uzedy sales of $191M (+63% YoY) but missed high-end expectations. Meanwhile, Olanzapine LAI’s FDA submission in December 2025 sets the stage for a potential H2 2026 approval, with European filings expected in Q2 2026. Royalties and milestones could inject $105M+ into Medincell’s pipeline.
Why Is Medincell’s Stock Struggling Despite Uzedy’s Growth?
Teva’s Q4 2025 report showed Uzedy (risperidone for schizophrenia) generated $55M in sales (+28% YoY), totaling $191M for the year. While growth is robust, the figures landed at the, spooking investors. Medincell earns 5%-10% royalties on net sales and remains eligible for $105M in commercial milestones tied to annual sales targets. Teva’s 2026 guidance of $250M-$280M suggests a 31%-47% growth trajectory—decent, but not the explosive leap some hoped for.
Olanzapine LAI: What’s the FDA Timeline?
Submitted on December 9, 2025, Olanzapine LAI’s FDA review follows a standard 10-month timeline (2 months for acceptance + 8 months for evaluation), pointing to a. Medincell stands to gain:
- 4M USD approval milestone
- 5%-10% royalties on net sales
- Up to $105M in commercial milestones
Europe’s EMA submission is slated for Q2 2026, with a 9-15 month review window. Given olanzapine’s popularity in EU schizophrenia treatment, this could be a.
How Does Medincell’s Pipeline Stack Up Financially?
Here’s the breakdown of Medincell’s revenue streams:
| Product | 2025 Sales | Royalty Rate | 2026 Projection |
|---|---|---|---|
| Uzedy | $191M | 5%-10% | $250M-$280M |
| Olanzapine LAI (US) | Pending | 5%-10% | Post-approval |
Christophe Douat, Medincell’s CEO, emphasized Teva’s commitment to “global accessibility” for Olanzapine LAI, calling Europe a “strategic market.”
FAQ: Medincell’s 2025-2026 Outlook
What’s driving Medincell’s stock pressure?
Uzedy’s Q4 sales growth (+28%) fell short of bullish expectations, though annual performance (+63%) remains strong.
When could Olanzapine LAI launch in the US?
FDA approval is likely in H2 2026, assuming standard review timelines hold.
What’s the European timeline for Olanzapine LAI?
EMA submission expected Q2 2026, with approval possible by late 2027.
